This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, T. M. E.
Right arrow Articles by Ilett, K. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, T. M. E.
Right arrow Articles by Ilett, K. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1099-1101, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01253-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Assessment of the Effect of Mefloquine on Artesunate Pharmacokinetics in Healthy Male Volunteers{triangledown}

Timothy M. E. Davis,1* Michelle England,1 Anne-Marie Dunlop,1 Madhu Page-Sharp,1 Nathalie Cambon,2 Thomas G. Keller,2 János L. Heidecker,2 and Kenneth F. Ilett1,3

School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia,1 Mepha Ltd., Pharmaceutical Research Development and Manufacture, Dornacherstrasse 114, 4147 Aesch, Switzerland,2 Clinical Pharmacology and Toxicology Laboratory, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia3

Received 5 October 2006/ Returned for modification 12 November 2006/ Accepted 4 December 2006

The effect of mefloquine on artesunate pharmacokinetics was assessed in 20 volunteers given artesunate for 3 days, followed ≥21 days later by combination therapy for 3 days. The areas under the concentration-time curve from 0 h to infinity for dihydroartemisinin, the active metabolite of artesunate, were similar on day 3 of the two dosing periods (P = 0.12), implying no interaction.

* Corresponding author. Mailing address: University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, P.O. Box 480, Fremantle, Western Australia 6959, Australia. Phone: (618) 9431 3229. Fax: (618) 9431 2977. E-mail: tdavis{at}cyllene.uwa.edu.au.

{triangledown} Published ahead of print on 18 December 2006.

Antimicrobial Agents and Chemotherapy, March 2007, p. 1099-1101, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01253-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»